Related Experiment Video

Updated: Jan 29, 2026

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.6K

Treatment of chemotherapy-associated cardiomyopathy

Amanda W Cai1, Marian H Taylor, Bhavadharini Ramu

  • 1Division of Cardiology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.

Current Opinion in Cardiology
|February 13, 2019
PubMed

Insights

Cancer survivors face increased risks of heart problems, including heart failure. This review covers managing cancer therapeutics-related cardiac dysfunction (CTRCD) and protecting heart health during cancer treatment.

Area of Science:

  • Cardiology
  • Oncology
  • Cardio-oncology

Background:

  • Increasing cancer survivor population necessitates focus on cardiovascular health.
  • Cardiovascular events and cancer therapeutics-related cardiac dysfunction (CTRCD) are significant causes of morbidity and mortality in cancer survivors.
  • CTRCD, including left ventricular dysfunction and heart failure, can limit cancer treatment options and reduce survival.

Purpose of the Study:

  • To review the latest literature on managing asymptomatic left ventricular dysfunction and heart failure in cancer patients.
  • To discuss prevention strategies and goal-directed medical therapies for chemotherapy-induced heart failure.
  • To explore advanced heart failure treatment options for this patient population.

Main Methods:

  • Review of recent literature and guidelines from cardiology and oncology societies.
  • Analysis of emerging evidence for prevention and treatment of heart failure related to chemotherapy.
  • Discussion of data extrapolated from the general heart failure population.

Main Results:

  • Current guidelines for CTRCD management are largely based on extrapolated data, lacking strong evidence specific to cancer patients.
  • Emerging evidence exists for managing heart failure from established chemotherapeutics.
  • There is a lack of trials for cardioprotective strategies against cardiotoxicity from newer targeted cancer therapies.

Conclusions:

  • Effective management of CTRCD is crucial for improving cancer patient outcomes.
  • Further research is needed to develop specific cardioprotective strategies for novel cancer therapies.
  • A comprehensive approach, from prevention to advanced treatments, is essential for managing heart failure in cancer survivors.
Abstract

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.4K

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
557
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
483
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
526
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
439
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
599
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
354